healthcare

Canaccord Genuity’s Top Biopharma Catalysts Coming This Quarter

Companies in the health care sector face great risk and great reward every time they make an announcement. Drug candidates passing clinical trials, gaining regulatory approval or being canceled can ...
Read Full Story »

Seattle Genetics Dips Despite FDA Win

Seattle Genetics Inc. (NASDAQ: SGEN) shares dipped on Monday following an update from the U.S. Food and Drug Administration (FDA). Essentially, the FDA granted Breakthrough Therapy Designation to Adcetris (brentuximab ...
Read Full Story »

Why Arena Pharma Is Winning Big With Its New Collaboration

Arena Pharmaceuticals Inc. (NASDAQ: ARNA) shares jumped early on Thursday after the company announced a new global license agreement with United Therapeutics Corp. (NASDAQ: UTHR). The goal of this collaboration ...
Read Full Story »

Synthorx Gears Up for IPO

Synthorx has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, although the ...
Read Full Story »

Short Sellers Pull Back on Major Pharma — With 1 Big Exception

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Raise the Stakes in Major Biotechs

The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Moderna Gears Up for IPO

Moderna has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, although the ...
Read Full Story »

Nektar Therapeutics and Pfizer Team Up in Cancer Collaboration

Nektar Therapeutics (NASDAQ: NKTR) shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer Inc. (NYSE: PFE) to evaluate several combination regimens in multiple cancer ...
Read Full Story »

Eli Lilly Dips Despite Solid Q3 Results

Eli Lilly and Co. (NYSE: LLY) released its third-quarter financial results before the markets opened on Tuesday. The pharma giant said that it had $1.39 in earnings per share (EPS) ...
Read Full Story »

Why Regulus Therapeutics Is Booming

Regulus Therapeutics Inc. (NASDAQ: RGLS) shares shot up on Tuesday after the company announced that it had amended and restructured its collaboration and license agreement with Sanofi. Under the terms ...
Read Full Story »

Vapotherm Gears Up for IPO

Vapotherm has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering. The company intends to price its 4.0 million shares in ...
Read Full Story »

What to Watch For When Eli Lilly Reports Tuesday Morning

Eli Lilly and Co. (NYSE: LLY) is scheduled to release its most recent quarterly results before the markets open on Tuesday. Consensus estimates from Thomson Reuters are calling for $1.35 ...
Read Full Story »

Why Clearside Biomedical Shares Were Halved

Clearside Biomedical Inc. (NASDAQ: CLSD) shares dropped sharply early on Monday after the firm reported results from its late-stage Sapphire trial. Ultimately, the Phase 3 results did not achieve the ...
Read Full Story »

Why the FDA Is Dragging Alkermes Down

Alkermes PLC (NASDAQ: ALKS) shares dropped 8% early on Friday in premarket trading after the company announced the results from its most recent meeting with the U.S. Food and Drug ...
Read Full Story »

The Drag on Teva’s Q3 Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) released its most recent earnings report before the markets opened on Thursday. The pharma giant said that it had $0.68 in earnings per share ...
Read Full Story »